Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge 2026

Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge 2026

The TRDNT Challenge is a NIH Common Fund prize competition, not a standard grant application. It is aimed at building a new class of RNA-targeting technologies that can be converted into practical therapies. The goal is to stimulate novel RNA-focused approaches for diseases where current treatment options are limited, where protein targets are hard to drug, or where the disease is tied to RNA dysfunction.

This page is written as a practical guide for teams and institutions evaluating whether this competition fits their stage, what to submit, and how to avoid avoidable disqualification risks.

Key details

What this opportunity is, in practical terms

Most funding opportunities in this repository are grants, fellowships, and scholarships with fixed award structures and PI-level compliance processes. TRDNT is different because the NIH is selecting submissions through a staged competition. That shift changes the workflow.

The competition starts with Phase I “Planning Comprehensive RNA-Targeting Technologies,” where applicants provide a concept package that must demonstrate how the idea can become a working prototype in later stages. At this stage, NIH is not asking for an already developed product. It is explicitly looking for endogenous RNA-targeting approaches that can address major medical need.

What makes TRDNT operationally distinct:

• It is explicitly a challenge with anticipated phases, not a single-call solicitation tied to one award number.
• Prize amounts are tied to performance over phases.
• The challenge is designed around discovery-to-demonstration logic and includes milestone-style progression.
• Eligibility and participation rules include registration, ownership, and licensing rules that do not always appear in standard federal grant systems.

The NIH has indicated Phase I, then possible Phase II and Phase III paths. Phase II and Phase III details are currently anticipated rather than fully published, and their launch timing is linked to ongoing announcements.

Why the competition matters for 2026/2027 applicants

TRDNT is positioned to align with two important realities in translational biomedicine:

• Many high-need diseases are hard to solve through existing druggable protein pathways.
• RNA biology is broad enough to address a larger number of conditions if innovators can deliver tools that transfer across diseases.

For applicants, this means the opportunity is most compelling for teams who are early in a concept cycle but can think across use cases. The competition is also useful for teams that cannot immediately support a full NIH grant submission but can defend a bold technical roadmap.

Unlike many grant calls where you must show extensive historical data, TRDNT explicitly asks whether your plan is novel, technically plausible, and scalable to future development. A project that is strong conceptually but still pre-proof-of-principle can still be competitive if the technical logic and execution plan are persuasive.

Who should apply and who probably should not

Strong candidates

Apply if you meet most of these criteria:

1. You have a problem framing tied to RNA biology and can identify a concrete disease-relevant need.
2. You can define a proposal that can plausibly move toward prototype development in the next stage.
3. You can document team capability for delivery (experts, facilities, or partnerships) without overpromising.
4. You are ready to make your title and executive summary suitable for public display in case of win.
5. You can prepare documents in NIH challenge format and respect strict registration rules.

This includes academic teams, research startups, molecular diagnostics groups, chemoproteomics groups, and computational teams that can bridge theory and implementable methods.

Probably not a fit

Avoid TRDNT if:

• You already have a mature, near-ready product that belongs better in licensing or grant cycles.
• You need a high-touch peer-review style program officer process and do not want a milestone competition environment.
• You cannot afford to expose the executive summary at all and have hard restrictions against broad public summary disclosure.
• You are using federal funds for your entire submission plan without checking grant terms and are unwilling to treat winner funds as program income if required.

Eligibility and participation structure explained clearly

The published rules define multiple participation pathways:

• Individuals can register and submit.
• Teams can form without being tied to an institution.
• Entities can submit under legal organization structures.

The page states that private entities must be U.S.-incorporated and U.S.-based to be winners, while non-U.S. participants can participate as team members but are not eligible for prize payment individually.

Important practical interpretation for institutions:

• If federal funds are used to prepare a submission, participation must align with the institution’s terms and your award terms.
• If federal-funded resources are used in a way that triggers program income, coordination with the relevant awarding office is required.

This is different from many NIH grant calls where proposal preparation itself is not usually framed as compliance-heavy around prize rules.

A key point: TRDNT explicitly separates winners and participants in the eligibility matrix. Registration may include broader participants, but only eligible participants can receive prize funds.

Deadlines and timeline: 2026 and the 2026/27 path

The page states:

• Launch: January 30, 2026
• Phase I submission open: May 30, 2026
• Phase I submission end: June 2026
• Phase I judging: July to August 2026
• Phase I winner announcements: August 2026

The page also states that additional phases are anticipated and not guaranteed, with the following planned windows:

• Phase II: launch around August 2026 with milestone windows November 2026 to January 2027, then main phase June/July 2027.
• Phase III: launch around November 2027 with outcomes expected into 2028/2029.

This timeline can change because the NIH notes that additional phases launch by separate announcements and are contingent on funded authority. Treat these as forward-looking windows, not guaranteed call dates.

Practical interpretation for planning

If you are considering 2026-2027 applications, do this:

• Enter Phase I as a proofing exercise in framing and team readiness.
• Do not wait for perfect data; provide a clear, believable path toward development.
• Use the July–August judging window to get feedback into your internal R&D planning, not to start from zero.
• Track NIH + portal announcements for Phase II launch and revised criteria, because the final mechanics can shift once later phases start.

What you must submit in Phase I

The requirement list for Phase I includes a written package, not a grant-style full project. The core elements are:

1. Title and executive summary (1 page)

   • Must include a brief description of the technology
   • Must explain impact on novel RNA-targeted therapies across disease classes
   • Avoid proprietary details in the public summary because it may be posted publicly for winners

2. Written proposal (10-page limit)

   • Health need and expected impact
   • Technical concept for RNA targeting
   • Detailed development plan
   • Team expertise and execution readiness
   • Roadblock identification and mitigation

3. References (1 page)

Submission formatting is strict: PDF, 8.5”x11”, minimum 11-point Arial, no smaller, and minimum 1-inch margins.

What “technical concept” should contain

A strong Phase I proposal should make it easy to evaluate readiness for Phase II:

• Clear mechanism class
• Intended use cases and disease relevance
• Development steps from idea to prototype
• How feasibility risk will be reduced at low cost
• Who delivers what and when
• Why this is not a generic or already established pathway

If you submit a technically weak outline in this first stage, the committee may not have enough basis to pass you forward to milestone evaluation.

How judging works, and how reviewers score you

The Phase I review is expert-evaluated and weighted toward four major dimensions:

• Completeness of required fields
• Potential clinical impact and unmet need coverage
• Novelty and technical originality
• Team feasibility and execution readiness, including ability to manage roadblocks

In practice, this means applicants should not only be scientifically interesting, but operationally credible. A technically brilliant idea without execution depth is less competitive than a strong idea with clear sequencing.

Common review mistakes that reduce score

• Submitting a broad proposal without clear endogenous RNA targeting.
• Submitting an already developed technology not suitable for ideation stage.
• Weak staffing argument with no execution plan.
• Ignoring public summary disclosure risk by putting proprietary markers in the summary.
• Submitting out of date compliance language or unsupported claims not tied to explicit development milestones.

Preparation and strategy: what to do before May 30, 2026

Week 1: Scope and fit

• Define one RNA mechanism class and one disease cluster.
• Explicitly justify why endogenous RNA targeting is central.
• Confirm the submission would be considered “new concept,” not mature development.

Week 2: Build a review-ready package

• Draft one-page summary in plain language that still signals impact.
• Prepare references and a short technical narrative with clear milestones.
• Include team profile and specific roles (who leads, who handles validation, who leads dissemination).

Week 3: Risk and resources review

• List required infrastructure and partnerships.
• Add at least one contingency for failure path.
• Describe exactly how prototype steps will be de-risked if the first concept fails.

Week 4: Rule compliance pass

• Ensure registration details and participant type are correct.
• Verify whether federal funds are being used and whether this creates program income implications.
• Check title and executive summary for disclosures and non-proprietary tone.

A practical edge here: challenge teams do better when the plan reads as credible for Phase II, not as a “paper proposal.”

Legal and administrative considerations (important)

TRDNT includes unusual but standard NIH challenge conditions:

• Participants grant NIH rights to reproduce and distribute the title and executive summary.
• You retain IP rights, but specific nonexclusive license rights to NIH for public display/repro are required.
• No automatic transfer of full IP ownership to NIH is required, but public disclosure is expected.
• If using federal funding support in development, confirm rules on source of funds and reporting.
• Prize tax treatment and payment methods are federal; winners should budget accordingly.

These rules are often overlooked by technical teams used to traditional grants. Challenge participants should involve legal, compliance, and grant administration advisors early, even if the team is small.

Who is this challenge best for (decision matrix)

A useful internal score can be this:

• Novelty (35%): Is this a distinct endogenous RNA mechanism not yet broadly developed?
• Need match (20%): Is there a clear medical need and multi-disease relevance?
• Execution readiness (25%): Can the team plausibly move to prototype and use case?
• Dissemination potential (10%): Is there a realistic public availability path?
• Rule fit (10%): Is your eligibility and registration posture clean?

Score 70/100 or above and submit. If below that and you are short mostly on execution feasibility, do a one-cycle rewrite before submission.

Common mistakes that invalidate or weaken applications

1. Treating the challenge as a standard R01-style scientific project and overloading with ungrounded background.
2. Applying a fully developed prototype to Phase I.
3. Submitting a submission that does not clearly target endogenous RNA.
4. Using federal funds without confirming allowed purpose against award terms.
5. Missing final submission timing or format requirements.
6. Not making public-disclosure risk decisions before drafting summary.
7. Treating Phase II as guaranteed and writing only to uncertain rules.
8. Assuming that all team members must be U.S.-citizens in any capacity.
9. Ignoring prize distribution mechanics (Team Captain/Point of Contact responsibility).

FAQ (concise, source-based)

Is this a grant or challenge?

It is a challenge with prize awards. It is not a standard NIH grant mechanism.

Can only one submission count?

A participant can generally submit one entry per phase under the stated rules; confirm current instructions before final submission.

Can a working prototype skip Phase I?

Phase I is ideation oriented. If you already have a developed prototype, NIH signals that Phase II is the more likely fit.

Can teams include non-U.S. members?

Yes for participation, but prize receipt rules are strict for non-U.S. participants.

Does this count toward NIH application limits?

NIH FAQ indicates challenge participation does not count toward the NIH six application limit.

Can this be applied to by a university team?

Yes, but federal fund use rules can apply and entity-level registration may be required depending on funding source.

What if Phase II/III details change?

They are anticipated and not fully fixed. Always check latest announcements before preparing phase transitions.

Official links and next steps

• Official TRDNT announcement: https://www.nih.gov/challenges/targeting-rna-disease-novel-technologies-trdnt-challenge
• NIH Common Fund program page: https://commonfund.nih.gov/venture/trdnt
• TRDNT funding opportunities table: https://commonfund.nih.gov/venture/trdnt/funding-opportunities
• TRDNT FAQ page: https://commonfund.nih.gov/venture/trdnt/faqs
• TRDNT registration/submission site: https://www.trdntchallenge.com

If you are deciding whether to invest in a Phase I package, the threshold question is not “do we have a novel idea,” but “can we submit a fully compliant, execution-ready idea package that can show a credible path toward prototype and use-case delivery if invited forward.”